For instance, primary prostate cancer patients harboring CTNNB1 genetic alterations positively correlate with earlier relapse [18], and CTNNB1 mutations occur at a higher frequency in plasma cell-free DNA (cfDNA) from CRPC patients that progressed on enzalutamide [74]. This evidence concerns the gene CTNNB1 and prostate cancer.